TARO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Taro Pharmaceutical Industries Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. (“Taro” or “the Company”) (
NYSE: TARO) and certain of its officers.
TARO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Taro Pharmaceutical Industries Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. (“Taro” or “the Company”) (
NYSE: TARO) and certain of its officers.
Taro Provides Results for Year Ended March 31, 2024
Taro Pharmaceutical Industries Ltd. (
NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2024.
Taro to Release Full Year Results on May 20, 2024
Taro Pharmaceutical Industries Ltd. (
NYSE: TARO) announced today that it plans to release its financial results for year ended March 31, 2024, after the close of market on Monday, May 20, 2024.
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Taro Shareholders Vote “FOR” Taro Sun Pharma Merger
Taro Pharmaceutical Industries Ltd. (
NYSE: TARO) (“Taro” or the “Company”) today announced that leading independent proxy advisory firms Institutional Shareholder Services (“ISS”) and Glass Lewis & Co. (“Glass Lewis”) have both recommended that Taro shareholders vote “FOR” the pending Merger transaction with Sun Pharmaceutical Industries Ltd. (“Sun Pharma”) at the upcoming May 22, 2024, extraordinary general meeting of shareholders.
TARO PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Taro Pharmaceutical Industries Ltd. - TARO
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Taro Pharmaceutical Industries Ltd. (
NYSE: TARO) to Sun Pharmaceutical Industries Limited. Under the terms of the proposed transaction, shareholders of Taro will receive $43.00 in cash for each share of Taro that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.
Taro Pharmaceutical Industries Ltd. (
NYSE: TARO) (“Taro” or the “Company”) today announced that it has called an extraordinary general meeting of its shareholders (the “Extraordinary General Meeting”), to be held on May 22, 2024, at 10:00 a.m., Israel time, and a class meeting (the “Ordinary Class Meeting” and together with the Extraordinary General Meeting, the “Meetings”) of the holders of the Company’s ordinary shares (the “Ordinary Shares”), to be held on May 22, 2024, at 11:00 a.m., Israel time, or immediately after the conclusion of the Extraordinary General Meeting, whichever is later, at Meitar Law Offices located at 16 Abba Hillel Road, 10th Floor, Ramat Gan, Israel. Following the Ordinary Class Meeting, a class meeting of the holders of the Company’s founders’ shares (the “Founder Shares”) will be held.
TARO PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Taro Pharmaceutical Industries Ltd. - TARO
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Taro Pharmaceutical Industries Ltd. (
NYSE: TARO) to Sun Pharmaceutical Industries Limited. Under the terms of the proposed transaction, shareholders of Taro will receive $43.00 in cash for each share of Taro that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Rover Group, Inc. (Nasdaq - ROVR), M.D.C. Holdings, Inc. (NYSE - MDC), Taro Pharmaceutical Industries Ltd. (NYSE - TARO), PGT Innovations Inc. (NYSE - PGTI)BALA CYNWYD, Pa., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Taro Provides Results for December 31, 2023
Taro Pharmaceutical Industries Ltd. (
NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and nine months ended December 31, 2023.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Rover Group, Inc. (Nasdaq - ROVR), M.D.C. Holdings, Inc. (NYSE - MDC), Taro Pharmaceutical Industries Ltd. (NYSE - TARO), PGT Innovations Inc. (NYSE - PGTI)BALA CYNWYD, Pa., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Taro to Release Third Quarter Results on January 25, 2024
Taro Pharmaceutical Industries Ltd. (
NYSE: TARO) announced today that it plans to release its financial results for the third quarter ended December 31, 2023, after the close of market on Thursday, January 25, 2024.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: M.D.C. Holdings, Inc. (NYSE - MDC), Cornerstone Financial Corporation (OTC - CFIC), Taro Pharmaceutical Industries Ltd. (NYSE - TARO), PGT Innovations Inc. (NYSE -BALA CYNWYD, Pa., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
TARO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Taro Pharmaceutical Industries Ltd. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Taro Pharmaceutical Industries Ltd. (
NYSE: TARO) to Sun Pharmaceutical Industries Limited for $43.00 per share in cash is fair to Taro shareholders.
Taro Provides Results for September 30, 2023
Taro Pharmaceutical Industries Ltd. (
NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and six months ended September 30, 2023.
Taro to Release Second Quarter Results on October 26, 2023
Taro Pharmaceutical Industries Ltd. (
NYSE: TARO) announced today that it plans to release its financial results for the second quarter ended September 30, 2023, after the close of market on Thursday, October 26, 2023.
Taro Provides Results for the Quarter Ended June 30, 2023
Taro Pharmaceutical Industries Ltd. (
NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter ended June 30, 2023.
Taro to Release First Quarter Results on July 26, 2023
Taro Pharmaceutical Industries Ltd. (
NYSE: TARO) announced today that it plans to release its financial results for the first quarter ended June 30, 2023, after the close of market on Wednesday, July 26, 2023.
Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2023
Taro Pharmaceutical Industries Ltd. (
NYSE: TARO) (“Taro”) announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2023, filed with the Securities and Exchange Commission (the “SEC”), is available within the Investor Relations section of Taro’s website at www.taro.com.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) Near the Top of Equities by Percentage Gain on 5/30Taro Pharmaceutical Industries Ltd. (
NYSE: TARO) is one of today’s top gainers. The company’s shares are currently up 23.11% on the day to $36.18.
Taro Provides Results for Year Ended March 31, 2023
Taro Pharmaceutical Industries Ltd. (
NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2023.
Taro to Release Full Year Results on May 23, 2023
Taro Pharmaceutical Industries Ltd. (
NYSE: TARO) announced today that it plans to release its financial results for the year ended March 31, 2023, after the close of market on Tuesday, May 23, 2023.
Taro Provides Results for December 31, 2022
Taro Pharmaceutical Industries Ltd. (
NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and nine months ended December 31, 2022.
Taro to Release Third Quarter Results on January 24, 2023
Taro Pharmaceutical Industries Ltd. (
NYSE: TARO) announced today that it plans to release its financial results for the third quarter ended December 31, 2022, after the close of market on Tuesday, January 24, 2023.
